PLAN FOR OBTAINING INFORMED CONSENT TO USE STORED HUMAN BIOLOGICAL MATERIALS

获得使用储存的人类生物材料的知情同意书的计划

• 批准号: 7606389
• 负责人: MICHAEL P DUBE
• 金额: $ 0.57万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606389
• 关键词: AIDS clinical trial group; Acquired Immunodeficiency Syndrome; Address; Archives; Biological; Blood; Blood specimen; Body Fluids; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; DNA; Enrollment; Funding; Future; Grant; Human; Informed Consent; Institution; Left; Protocols documentation; Research; Research Personnel; Resources; Sampling; Source; Specimen; Tissues; United States National Institutes of Health; Urine; cohort; design; genetic analysis

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This multi-center protocol was designed to obtain the appropriate informed consent to archive left-over human biological materials, blood, urine, tissue, or other body fluids, that are collected during all AACTG trials. An additional blood sample may be collected as a source of human DNA for possible genetic analyses. These samples are an important resource for addressing research questions in the future that cannot be anticipated presently. In addition, the specimens represent unique cohorts, which may not be reproducible in the future. No more than 50,000 subjects will be enrolled all across the AIDS Clinical Trials Units.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 该多中心方案旨在获得适当的知情同意，以存档所有 AACTG 试验期间收集的剩余人类生物材料、血液、尿液、组织或其他体液。 可以收集额外的血液样本作为人类 DNA 的来源，用于可能的遗传分析。 这些样本是解决目前无法预见的未来研究问题的重要资源。 此外，这些样本代表了独特的群体，将来可能无法重现。 所有艾滋病临床试验单位将招募不超过 50,000 名受试者。